 |
|
Discussing the Depression-Pain Dyad With Patients—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We find Dr Daniell's hypothesis about OPIAD and depression provocative. Whether the degree of androgen deficiency induced by opioid use is sufficient to cause clinical depression and, if so, in what proportion of patients are questions warranting further investigation. We are not familiar with published data showing that depression in opioid-treated patients is more refractory to antidepressant therapy, though Dr Daniell's experience could be corroborated in future trials. One would need to carefully control for other confounders, separate from opioid use, which might complicate depression response in patients with chronic pain. We would be cautious about advocating testosterone treatment for depression in patients receiving opioids until further trials with OPIAD have been conducted.
We agree with Dr Regalbuto that patient beliefs or causal attribution regarding their somatic symptoms and the stigma related to mental illness are common barriers to the recognition and subsequent treatment of depression and anxiety . . . [Full Text of this Article]
Matthew J. Bair, MD, MS;
Rebecca L. Robinson, MS
Indianapolis, Ind
Wayne Katon, MD
Seattle, Wash
Kurt Kroenke, MD
Indianapolis
RELATED ARTICLES
Discussing the Depression-Pain Dyad With Patients
Thomas J. Beckman
Arch Intern Med. 2004;164(7):804-805.
EXTRACT
| FULL TEXT
Depression and Pain Comorbidity: A Literature Review
Matthew J. Bair, Rebecca L. Robinson, Wayne Katon, and Kurt Kroenke
Arch Intern Med. 2003;163(20):2433-2445.
ABSTRACT
| FULL TEXT
|
